A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs CRS 207 (Primary) ; Tumour cell vaccine-GVAX (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 27 Apr 2017 Status changed from discontinued to completed.
    • 28 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 09 Nov 2015 Updated safety and efficacy data were presented at the 2015 Society for Immunotherapy of Cancer Annual Meeting, according to an Aduro BioTech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top